Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic

Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a... Am J Cardiovasc Drugs (2018) 18:143–151 https://doi.org/10.1007/s40256-018-0264-5 SHORT COMMUNICATION Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic 1 1 Elizabeth K. Pogge Lindsay E. Davis Published online: 17 February 2018 Springer International Publishing AG, part of Springer Nature 2018 Abstract blood pressure of 6 mmHg with no significant changes in Objective The objective of this research was to describe serum creatinine, blood urea nitrogen, or potassium levels. the use of pharmacist-managed sacubitril/valsartan therapy Conclusions With close monitoring and follow-up, ARNi in a multi-center, outpatient cardiac group. therapy was a safe alternative to ACEi/ARB therapy for Background Sacubitril/valsartan, an angiotensin receptor- chronic symptomatic HFrEF when initiated within a neprilysin inhibitor (ARNi), is a novel agent for the treat- pharmacist clinic. ment of heart failure. An ARNi is recommended by national guidelines to be used in place of angiotensin- Abbreviations ACEi Angiotensin-converting enzyme converting enzyme inhibitor (ACEi) or angiotensin recep- tor blocker (ARB) therapy for patients who remain inhibitor AHA American Heart Association symptomatic. Methods A retrospective chart review was performed to ARB Angiotensin receptor blocker identify patients initiated and fully titrated on sacubi- ARNi Angiotensin receptor-neprilysin tril/valsartan therapy from July 7, 2015 to March http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic

Loading next page...
 
/lp/springer_journal/evaluating-the-safety-and-tolerability-of-sacubitril-valsartan-for-xa7s2j8gcf
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
D.O.I.
10.1007/s40256-018-0264-5
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2018) 18:143–151 https://doi.org/10.1007/s40256-018-0264-5 SHORT COMMUNICATION Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic 1 1 Elizabeth K. Pogge Lindsay E. Davis Published online: 17 February 2018 Springer International Publishing AG, part of Springer Nature 2018 Abstract blood pressure of 6 mmHg with no significant changes in Objective The objective of this research was to describe serum creatinine, blood urea nitrogen, or potassium levels. the use of pharmacist-managed sacubitril/valsartan therapy Conclusions With close monitoring and follow-up, ARNi in a multi-center, outpatient cardiac group. therapy was a safe alternative to ACEi/ARB therapy for Background Sacubitril/valsartan, an angiotensin receptor- chronic symptomatic HFrEF when initiated within a neprilysin inhibitor (ARNi), is a novel agent for the treat- pharmacist clinic. ment of heart failure. An ARNi is recommended by national guidelines to be used in place of angiotensin- Abbreviations ACEi Angiotensin-converting enzyme converting enzyme inhibitor (ACEi) or angiotensin recep- tor blocker (ARB) therapy for patients who remain inhibitor AHA American Heart Association symptomatic. Methods A retrospective chart review was performed to ARB Angiotensin receptor blocker identify patients initiated and fully titrated on sacubi- ARNi Angiotensin receptor-neprilysin tril/valsartan therapy from July 7, 2015 to March

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Feb 17, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off